ASCLF News and Press, Ascletis Pharma Inc. From 12/07/22

Ascletis Pharma ( OTCPK:ASCLF ) said China's National Medical Products Administration (NMPA) approved its investigational new drug (IND) application to start a trial of oral drug ASC11 for COVID-19. The goal of the phase 1 trial, which is expected to be completed within Q1 2023, ...

Summary Beijing AIM Vaccine conducted a very small IPO on the Hong Kong exchange, raising just US$20 million, which netted the company only US$10 million. Interest in the offering was low, with less than 1% of the company shares sold in the offering. Shanghai SciClone Pharma has b...

Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development and sales milestones. Shanghai Zai Lab has changed its Hong Kong listing from secondar...

Nanjing InxMed announced a $15 million B+ funding round to develop its novel therapies that target the stroma microenvironment and drug resistance for hard-to-treat solid tumors. InxMed will use the funds for US/China clinical trials of its lead drug, IN10018. US-based Coherus Bioscie...

Wuhan Binhui Biopharm closed a $47 million Series B financing to support its R&D of oncolytic virus products. Amoy Diagnostics, a Shanghai novel molecular diagnostics company, signed a collaboration agreement to develop companion diagnostics for AstraZeneca drugs. Hangzhou Asc...

Ascletis Pharma (OTCPK:ASCLF) said data from antiviral cellular assays suggested that its drug ASC11 showed potential to be effective treatment for COVID-19. The Chinese company said that in antiviral cellular assays, antiviral potency of ASC11 was 31-fold of that of Nirmatrelvir, a comp...

A US FDA oncology advisory panel rejected the NDA submitted by Innovent and Lilly for their partnered anti-PD-1 antibody, voting 14-1 against approval. Hangzhou's Huadong Medicine acquired Asia-Pacific (ex-Japan) rights to a bi-functional immunotherapy from Akso Biopharma of Menlo Par...

China-based venture capital firm Qiming has raised more than $500 million to invest in shares of listed healthcare companies. The Springhill Fund, as it is called, will have an initial regional focus on Greater China and Asia. Shanghai Junshi Bio formed an mRNA Joint Venture with Hang...

Beijing InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen in a $937.5 million deal. Suzhou's Kintor Pharma will start a US Phase II trial of its treatment for male pattern baldness. Ascletis Pharma of Hangzhou started a China bridging trial of its FXR agonist f...

Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. Beijing's BeiGene presented positive interim results from Phase III trial that compared its BTK candidate to AbbVie's Imbruv...